Mainstream

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing

Post ContenttlphRead More

You might also be interested in reading Koninklijke BAM projects 5% EBITDA margin for 2025 amid strategic expansion efforts.

May 15, 2025
In Mainstream